Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-01-17
2006-01-17
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093200, C435S320100, C435S325000, C435S455000
Reexamination Certificate
active
06986887
ABSTRACT:
The subject invention pertains to materials and methods for preparing multi-potential stem cells having a pre-selected expression of MHC antigens. Stem cells of the subject invention can be used to generate histocompatible tissues/organs for transplantation. The process of the subject invention comprises the use of targeting vectors capable of gene knockout, insertion of site-specific recombination cassettes, and the replacement of histocompatibility alleles in the stem cell. Novel knockout vectors are used to delete designated regions of one chromosome. Recombination cassette vectors are then used to delete the same region on the second chromosome and deposit a site-specific recombination cassette which can be utilized by replacement vectors for inserting the new MHC genes on the chromosome of the engineered cell. The subject invention also pertains to cells, tissues, and transgenic mammal prepared using the methods and materials of the invention.
REFERENCES:
patent: 5486359 (1996-01-01), Caplan et al.
patent: 5574205 (1996-11-01), Kucherlapati et al.
patent: 5679340 (1997-10-01), Chappel
patent: 6030833 (2000-02-01), Seebach et al.
patent: WO 95/26741 (1995-10-01), None
patent: WO 92/22362 (1996-07-01), None
Bradley et al., 1992, Biotechnology, vol. 10, p. 534-539.
Houdebine, L-M, 1994, Journal of Biotechnology, vol. 34, p. 269-287.
Brenneman et al., 1996, Proc. Natl. Acad. Sci., vol. 93, pp. 3608-3612.
Ellis et al., 2001, PNAS, vol. 98, No. 12, p. 6742-6746.
Dyer et al., 1992, Transplantation Proceedings, vol. 24, No. 6, p. 2454.
Cosgrove et al., 1991, Cell, vol. 66, p. 1051-1066.
Leonard et al., 1995, Immunological Reviews, vol. 148, pp. 97-114.
Sigmund, C., Jun. 2000, Arterioscler. Thromb. Vasc. Biol., p. 1425-1429.
Houdebine, L-M., 2002, Journal of Biotechnology, vol. 98, p. 145-160.
Eck et al., 1996, Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, p. 77-101.
Gorecki, D., 2001, Expert Opin. Emerging Drugs, 6(2): 187-198.
Armstrong, J. W. et al. “Class I and class II major histocompatibility molecules play a role in bone marrow-derived macrophage development”Journal of Leukocyte Biology, 1994, pp. 658-661, vol. 55.
Auchincloss, H. “Xenogeneic Transplantation”Transplantation, 1988, pp. 1-20, vol. 46.
Benichou, G. et al. “Indirect T-cell allorecognition: perspectives for peptide-based therapy in transplantation”Immunology Today, 1997, pp. 67-71, vol. 18, No. 2.
Bidwell, J. “Advances in DNA-based HLA-typing methods”Immunology Today, 1994, pp. 303-307, vol. 15, No. 7.
Bradley, A. et al. “Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines”Nature, 1984, pp. 255-256, vol. 309.
Capecchi, M. R. “Targeted Gene Replacement”Scientific American, 1994, pp. 52-59, vol. 3.
Carlow, D. A. et al. “Class I (H-2Kb) gene transfection reduces susceptibility of YAC-1 lymphoma targets to natural killer cells”Eur. J. Immunol., 1990, pp. 841-846, vol. 20.
David-Watine, B. et al. (1990) “The regulation and expression of MHC class I genes”Immunology Today., 1990, pp. 286-292, vol. 11, No. 8.
Drezen, J. M. et al. “Different regulation of class I gene expression in the adult mouse and during development”J. Immunol., 1992, pp. 429-437, vol., 149.
Evans, M. J. et al. “Establishment in culture of pluripotential cells from mouse embryos”Nature, 1981, pp. 154-156, vol. 292.
Faustman, D., Coe, C. “Prevention of Xenograft Rejection by Masking Donor HLA Class I Antigens”Science, 1991, pp. 1700-1702, vol. 252.
Faustman, D. “Strategies for circumventing transplant rejection: modification of cells, tissues and organs”Trends in Biochem. Tech., 1995, pp. 100-105, vol. 13.
Galli-Taliadoros, L. A. et al. “Gene knock-out technology: a methodological overview for the interested novice”J. Immunol. Methods, 1995, pp. 1-15, vol. 181.
Goss, J. A. et al. “Intrathymic injection of donor alloantigens induces specific tolerance to cardiac allografts”Transplantation, 1993, pp. 166-173, vol. 56.
Isobe, M. et al. (1992) “Specific Acceptance of Cardiac Allograft After Treatment with Antibodies to ICAM-1 and LFA-1”Science, 1992, pp. 1125-1127, vol. 255.
Joyner, A. J. et al. “Production of a mutation in mouse En-2 gene by homologous recombination in embryonic stem cells”Nature, 1989, pp. 153-156, vol. 338.
Karre, K. et al. “Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy”Nature, 1986, pp. 675-678, vol. 319.
Kim, M. et al. “Divergent Effects of H-2K and H-2D Genes on Sensitivity of BL6 Melanoma Cells to NK Cells or TNF-Mediated Cytotoxicity”Cellular Immunology, 1994, pp. 358-371, vol. 155.
Lechler, R. I. et al. “Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells”J. Exp. Med., 1982, pp. 31-41, vol. 155.
Markmann, J. F. et al. (1994) “Genetically engineered grafts to study xenoimmunity: A role for indirect antigen presentation in the destruction of major histocompatibility complex antigen deficient xenografts”Surgery, 1994, pp. 242-249, vol. 116, No. 2.
Mansour, S. L. et al. “Disruption of the proto-oncogeneint-2in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes”Nature, 1988, pp. 348-352, vol. 336.
Pearson, T. C. et al. “Induction of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody”Transplantation, 1992, pp. 475-483, vol. 54, No. 3.
Schwartzberg, P. L. et al. “Germ-Line Transmission of a c-abl Mutation Produced by Targeted Gene Disruption in ES Cells”Science, 1989, pp. 799-803, vol. 246.
Shim, H. et al. “Isolation of Pluripotent Stem Cells from Cultured Porcine Primordial Germ Cells”Biology of Reproduction, 1997, pp. 1089-1095, vol. 57.
Siebers U., et al., “Bioartificial Pancreas: Islet Survival and Interleukin-1 Action”Transplantation Proceedings, 1990, pp. 2035-2036, vol. 22, No. 4.
Smithies, O. et al. “Insertion of DNA sequences into the human chromosomal β-globin locus by homologous recombination”Nature, 1985, pp. 230-234, vol. 317.
Stange, J. et al. “Hepatocyte encapsulation—initial intentions and new aspects for its use in bioartificial liver support”The International Journal of Artificial Organs, 1996, pp. 45-48, vol. 19.
Te Riele, H. et al. “Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs”Proc. Natl. Acad. Sci., 1992, pp. 5128-5132, vol. 89.
Thomas, K. R. et al. (1987) “Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells”Cell, 1987, pp. 503-512, vol. 51.
Wong, W. “Syngeneic bone marrow expressing a single donor class I MHC molecule permits acceptance of a fully allogenic cardiac allograft”Transplantation, 1996, pp. 1462-1468, vol. 62.
Pursel, V. G. et al. “Expression and performance in transient pigs”J. Reprod. Fert. Suppl., 1990, pp. 235-245, vol. 40.
Palmiter, R. D. et al. “Mettallothionein-human GH fusion genes stimulate growth of mice”Science, 1983, pp. 809-814, vol. 222.
Houdebine, L.-M. “Production of pharmaceutical proteins from transient animals”Journal of Biotechnology, 1994, pp. 269-287, vol. 34.
Bradley, A. et al. “Modifying the mouse: Design and desire”Bio/Technology, 1992, pp. 534-539, vol. 10.
Seamark, R. F. “Progress and emerging problems in livestock transgenesis: a summary perspective”Reprod. Fertil. Dev., 1994, pp. 653-657, vol. 6.
Kappel, C. A. et al. “Regulating gene expression in transgenic animals”Current Opinion in Biotechnology, 1992, pp. 548-553, vol. 3.
Hammer, R. E. et al. “Genetic Engineering of Mammalian Emb
Lawman Michael J. P.
Lawman Patricia
Chen Shin-Lin
Edwards & Angell LLP
Morphogenesis, Inc.
LandOfFree
Universal stem cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Universal stem cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Universal stem cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3560899